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E-mail: naofumim@kenroku.kanazawa-u.ac.jpPim-3 is a member of the Provirus integrating site Moloney murine
leukemia virus (Pim) family, which belongs to the Ca2+ ⁄ calmodu-
lin-dependent protein kinase (CaMK) group and exhibits serine ⁄
threonine kinase activity. Similar to other members of the Pim
family (i.e. Pim-1 and Pim-2), Pim-3 can prevent apoptosis and pro-
mote cell survival and protein translation, thereby enhancing cell
proliferation of normal and malignant cells. Pim-3 is expressed in
vital organs, such as the heart, lung, and brain. However, minimal
phenotypic changes in Pim-3-deficient mice suggest that Pim-3
may be physiologically dispensable. Pim-3 expression is enhanced
in several cancer tissues, particularly those of endoderm-derived
organs, including the liver, pancreas, colon, and stomach. The
development of hepatocellular carcinoma is accelerated in mice
expressing the Pim-3 gene selectively in the liver only when these
mice are treated with a hepatocarcinogen, indicating that Pim-3
can act as a promoter but not as an initiator. Moreover, inhibition
of Pim-3 expression can retard in vitro cell proliferation of hepato-
cellular, pancreatic, and colon carcinoma cell lines by promoting
cell apoptosis. Furthermore, a Pim-3 kinase inhibitor has been
reported to inhibit cell proliferation in an in vivo xenograft model
using a human pancreatic cancer cell line without inducing any
major adverse effects. Thus, Pim-3 kinase may be a candidate mol-
ecule for the development of molecular targeting drugs against
cancer. (Cancer Sci 2011; 102: 1437–1442)
P im-3 was initially identified as a novel gene that is inducedby membrane depolarization or forskolin in a rat pheochro-
mocytoma cell line (namely PC12 cells) and was designated as
kinase induced by depolarization (KID)-1.(1) However, KID-1
was renamed Pim-3 because it showed high sequence similarity
with the proto-oncogene Provirus integrating site Moloney mur-
ine leukemia virus (Pim) family proteins.(2) The Pim family is
part of the Ca2+ ⁄ calmodulin-dependent protein kinase (CaMK)
group (http://www.kinase.com/human/kinome, accessed May
13, 2011) and was named as such because the gene locus of
Pim-1, the prototype Pim kinase, was originally identified as a
Proviral Insertion site of Moloney murine leukemia virus.(3)
Subsequent studies revealed that Pim-1 and myc can contribute
cooperatively to the development of experimental T cell lym-
phoma.(4) In addition, Pim-2 has been identified as a proviral
integration site associated with the rapid development of malig-
nant T cell lymphoma.(5)
Screens using retroviral mutagenesis have uncovered two
types of serine ⁄ threonine kinases, namely the Akt(6) and Pim(7)
kinases, as potent suppressors of myc-induced apoptosis. More-
over, Pim and Akt kinases are critical components of overlap-
ping, but independent, pathways that can promote the growth and
survival of non-transformed hematopoietic cells.(8) Because both
Pim and Akt kinases can phosphorylate similar sets of substratesdoi: 10.1111/j.1349-7006.2011.01966.x
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proposed that these kinases are categorized as survival kinases.(9)
In various types of tumors, Akt is aberrantly activated and ⁄or
phosphatase and tensin homolog (PTEN), an Akt inhibitory
molecule, is frequently deleted.(9) Based on these observations,
drugs targeting the Akt axis have been developed for the treat-
ment of cancer.(10) Similarly, Pim kinases are aberrantly
expressed in a wide variety of tumors(11) and therefore may be a
good molecular target in cancer treatment. Here, we discuss
mainly the new member of the Pim kinase family (i.e. Pim-3) and
its potential roles in tumor development and progression.
Structure of the Pim-3 Protein
Human Pim genes are found at different chromosomal locations
in the human genome: Pim-1 is located on chromosome 6p21.2,
Pim-2 is located on the X chromosome and Pim-3 is located on
chromosome 22q13.(11) The mRNA transcripts for Pim are
encoded by six exons with large 5¢ and 3¢ untranslated regions
containing a G ⁄C-rich region and five copies of AUUA destabi-
lizing motifs, respectively. The Pim-1 and Pim-2 genes can gen-
erate two and three isoforms, respectively, by using alternative
translation initiation sites, although all these isoforms retain
their serine ⁄ threonine kinase activity.(12,13) In contrast, a single
species of Pim-3 mRNA has been detected in various human
organs.(14)
The open reading frame of Pim-3 mRNA encodes a protein
consisting of 326 amino acids with a calculated molecular
weight of 35 861 (Fig. 1).(14) In contrast with most kinases, the
Pim-3 protein has no regulatory domains, similar to Pim-1 and
Pim-2. Human Pim-3 protein shows a high degree of identity
with human Pim-1 (57.1%) and Pim-2 (44.0%) at the amino acid
level, even in the kinase domains (Fig. 1), as well as to rat Pim-
3 (95.0%), mouse Pim-3 (95.0%), quail Pim (73.9%), and Xeno-
pus (Pim-1; 68.7%).(14)
The crystal structure of the Pim-3 protein has not yet been
obtained, but several independent groups have reported the
crystal structure of Pim-1 and Pim-2 in the presence or absence
of their inhibitors.(15–17) The Pim-1 kinase structure adopts a
two-lobe kinase fold with a deep, intervening cleft.(15) The
N-terminal lobe is composed primarily of b-sheets, whereas
the C-terminal lobe is comprised of a-helices. The two domains
are connected via the hinge region (residues 121–126; http://
www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=30738,
accessed May 13, 2011). Several residues in the cleft have been
identified as the ATP binding site (Fig. 1). Moreover, the ATP
binding pocket in Pim-1 is open in either the presence or absenceCancer Sci | August 2011 | vol. 102 | no. 8 | 1437–1442
Fig. 1. Amino acid alignment of human Pim family
proteins.(14) The amino acid sequence of human
Pim family kinases is aligned and the residues
identical to human Pim-3 are highlighted. The
hinge region is indicated by the box. White and red
letters indicate residues important for ATP binding
and substrate specificity, respectively.of ATP,(15) indicating that the Pim-1 kinase active site is main-
tained in an active conformation. Similar findings have been
reported for the structure of Pim-2 kinase.(17) This may account
for the association between protein levels of Pim-1 and Pim-2
and overall kinase activity.(11) Given the high sequence similar-
ity between the Pim proteins, it is expected that Pim-3 kinase
will have a similar structure to that described for Pim-1 and
Pim-2 and that it will also be constitutively active. Furthermore,
several residues have been identified as important for determin-
ing the specificity of Pim-1 kinase and these residues are con-
served between Pim-1, Pim-2, and Pim-3 (Fig. 1).(16)
Expression of Pim-3
The expression of Pim-3 mRNA has been detected in various
human tissues, including the heart, brain, lung, kidney, spleen,
placenta, skeletal muscle, and peripheral blood leukocytes.(14)
However, Pim-3 mRNA has not been found in the colon, thy-
mus, liver, or small intestine.(14) In addition, Pim-3 is expressed
in endothelial cells.(18) In the brain, Pim-3 and Pim-1 are
induced in the hippocampus in response to stimuli that elicit
long-term potentiation.(2) Focal cerebral ischemia enhances
Pim-3 mRNA expression in the peri-infarction cortex at early
time points.(19) Similarly, ischemia–reperfusion injury enhances
intracardiac Pim-3 expression through a p38-mediated signaling
pathway.(20) In the mouse embryo, all Pim genes are expressed
in distinct manners at stages later than embryonic day (E) 14.(21)
In mouse embryos, in situ hybridization has detected Pim-3
gene expression in the liver, the periphery of the pancreas, in
the secretory epithelium of the stomach, and in the intestinal
epithelium.(21) Moreover, Pim-3 has been detected in the
kidney, lungs, thymus, and central nervous system of mouse
embryos.(21)
A panel of human Ewing’s family tumor cell lines has been
shown to express Pim-3 mRNA.(22) Moreover, enhanced Pim-3
mRNA expression is observed in nasopharyngeal carcinoma cell
lines.(23) Similarly, we revealed that Pim-3 protein is barely
detected in normal adult endoderm-derived organs such as the1438liver, pancreas, colon, and stomach; however, its expression is
augmented in premalignant and malignant lesions of these
organs (Table 1).(14,24–26) The staining pattern in these tumors is
mostly cytoplasmic. In the liver, Pim-3 protein is detected in
regenerative nodules and adenomatous hyperplasia, lesions with
precancerous potential adjacent to hepatocellular carcinoma
(HCC) cells, at a higher frequency than in HCC cells.(14) Simi-
larly, in the colon and stomach, Pim-3 protein is detected in ade-
noma tissues with a higher incidence than in adenocarcinoma
tissues.(25,26) These observations suggest that aberrant Pim-3
expression can occur in the early phase of carcinogenesis.
The Ewing sarcoma breakpoint region-1/E26 transformation-
specific (EWS ⁄ETS) fusion proteins are pathognomonic for
Ewing’s sarcoma tumors and arise from the chromosomal trans-
locations that fuse a portion of the amino-terminal region of
EWS to one of five members of the ETS family transcription
factors, namely Friend leukemia integration (FLI), v-ets avian
erythroblastosis virus E26 oncogene homolog (ERG), fifth
Ewing sarcoma variant (FEV), ets variant gene 1 (ETV1), and
E1A enhancer binding protein (E1AF).(27) Deneen et al.(22)
demonstrated that Pim-3 can be upregulated by EWS ⁄ETS
fusion proteins, suggesting that ETS protein can regulate Pim-3
gene expression.
To delineate the molecular mechanisms underlying constitu-
tive Pim-3 expression in human pancreatic cancer cells, we
characterized the 5¢-flanking region of the human Pim-3 gene.
The human Pim-3 gene contains a canonical TATA box and
putative binding sites for several known transcription factors,
such as signal transducer and activator of transcription (Stat) 3,
Sp1, Ets-1, and nuclear factor (NF)-jB (Fig. 2a).(28) Although
Pim-3 expression is enhanced in murine embryonic stem cells
by leukemia inhibitory factor ⁄gp130-dependent signaling and
the Stat3 transcription factor,(29) the transfection of a dominant
negative form of Stat3 failed to inhibit the promoter activity of
the Pim-3 gene in human pancreatic cancer cells.(28)
Using luciferase expression vectors linked to the 5¢-flanking
deletion mutants of the human Pim-3 gene, we demonstrated
that the region between )264 and )164 bp is essential fordoi: 10.1111/j.1349-7006.2011.01966.x
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Table 1. Expression patterns for Pim kinases in various types of
malignancies and their biological functions in carcinogenesis
Pim-1 Pim-2 Pim-3
Expression in
Prostate adenocarcinoma + + ND
Squamous cell carcinoma of head
and neck
+ ND ND
Nasopharyngeal carcinoma ND ND +
Oral squamous cell carcinoma + ND ND
Gastric cancer + ND +
Colon carcinoma ND ND +
Pancreatic cancer + ND +
Hepatocellular carcinoma ND + +
Ewing’s sarcoma ND ND +
Acute myeloid leukemia ND + ND
B Cell chronic lymphocytic leukemia ND + ND
Primary mediastinal large B cell
lymphoma
+ ND ND
Mantle cell lymphoma + + ND
Diffuse large B cell lymphoma + + ND
Biological functions in carcinogenesis
Inhibition of apoptosis + + +
Phosphorylation and inactivation of Bad + + +
Cell cycle progression + + +
Phosphorylation of Cdc25A + ND ND
Phosphorylation of C-TAK1 + ND ND
Phosphorylation of p27 + + +
Inactivation of FoxO1a and FoxO3a + ND ND
5¢-Cap-dependent protein translation ND ND +
Induction of PGC-1a expression ND ND +
Induction of c-Myc expression ) ) +
Phosphorylation of c-Myc + + ND
Coactivator of c-Myc + + ND
Phosphorylation of histone H3 + ND ND
Endothelial cell tube formation ND ND +
ND, not determined; C-TAK1, Cdc25C-associated kinase 1; PGC-1a,
peroxisome proliferator-activated receptor c coactivator 1a.constitutive Pim-3 gene expression.(28) This region contains
one NF-jB, two Sp1, and two Ets-1 binding sites (Fig. 2a).
The mutation in the NF-jB binding site failed to reduce lucif-
erase activity(28) and it is therefore unlikely that NF-jB can
contribute to constitutive Pim-3 gene expression in human pan-
creatic cancer cells (in contrast with the Pim-1 gene, which can
be induced by CD40-mediated signals in an NF-jB-dependent
manner).(12) Further examination has revealed that two Sp1
binding sites and the distal Ets binding site are crucial for con-Fig. 2. (a) Structure of the 5¢-flanking region of
the human Pim-3 gene with potential binding sites
for known transcription factors. (b) Promoter
activities driven by the 5¢-flanking region of the
human Pim-3 gene, which is either deleted or
mutated.(28) The mutation in each binding site is
indicated by an ‘‘·’’.
Mukaida et al.stitutive Pim-3 gene expression in human pancreatic cancer
cells (Fig. 2b).(28) The crucial role of Ets-1 in constitutive
Pim-3 gene expression is further supported by our observations
that the overexpression of Ets-1 enhances Pim-3 expression,
whereas the transfection of a dominant negative form of Ets-1
or Ets-1 siRNA reduces Pim-3 expression in human pancreatic
cancer cells.(28) Because the expression of both Ets-1 and Sp1
is enhanced in various types of cancer, including pancreatic
cancer,(30,31) it is likely that Ets-1 and Sp1 act cooperatively to
induce constitutive Pim-3 gene expression, as has been seen for
their other target genes.(32)
The translation of Pim-1 mRNA is regulated by several mech-
anisms, including microRNA.(11) However, it remains unknown
whether Pim-3 translation is regulated in a similar manner.
Pim-1, and probably Pim-3, can autophosphorylate some of their
serine residues.(16) Serine ⁄ threonine phosphatase and protein
phosphatase 2A dephosphorylate Pim-1 and Pim-3 proteins,
eventually decreasing their protein levels.(33)
Roles in Carcinogenesis
We observed that Pim-3 shRNA treatment decreases in vitro
proliferation of various types of cancer cells by enhancing the
apoptosis of these cells (Table 1).(14,24,25) The proapoptotic
BH3-only protein Bad is a major regulator of apoptosis.
Unphosphorylated Bad binds, and eventually inactivates, antia-
poptotic family members, primarily Bcl-XL, but also Bcl-2,
whereas phosphorylation of Bad at Ser112, Ser136, and Ser155
impairs its binding to Bcl-XL and promotes the sequestration of
Bad from the surface of the mitochondria to the cytosol by the
protein 14-3-3.(34,35) By phosphorylating Bad at Ser112, Pim-1
and Pim-2 inactivate it, eventually inhibiting apoptosis.(36,37)
Similarly, enforced expression of Pim-3 increases the amount of
Bad phosphorylated at Ser112, whereas Pim-3 shRNA treatment
decreases Bad phosphorylation at Ser112.(24,25) Thus, it is likely
that Pim-3 inhibits the apoptosis of cancer cells and eventually
furthers carcinogenesis (Fig. 3).
Forced expression of Pim-3 can promote anchorage-indepen-
dent growth and coexpression of a kinase-deficient Pim-3
mutant can attenuate EWS ⁄FLI-mediated NIH 3T3 tumorigene-
sis in immunodeficient mice.(22) These observations suggest the
potential involvement of Pim-3 in this carcinogenesis model.
To delineate the roles of Pim-3 in carcinogenesis in more
detail, we prepared mice that express the human Pim-3 transgene
abundantly and selectively in the liver.(38) These mice are born
at a Mendelian ratio, are fertile, and do not exhibit any apparent
pathological changes in the liver until 1 year after birth. The
Pim-3-transgenic mouse-derived hepatocytes exhibit enhanced
phosphorylation of Bad112, but contain a similar proportion ofCancer Sci | August 2011 | vol. 102 | no. 8 | 1439
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Fig. 3. Presumed mechanisms involved in Pim-3-mediated inhibition
of apoptosis.
Fig. 4. Presumed roles of Pim-3 in tumorigenesis. Solid and broken
lines indicate the functions attributed to Pim-3 and other Pim kinases,
respectively. AMPK, AMP-activated protein kinase; PGC-1a, peroxisome
proliferator-activated receptor c coactivator 1a; C-TAK1, Cdc25C-
associated kinase 1.apoptotic cells compared with wild-type mice. Moreover, Pim-
3-transgenic mouse-derived hepatocytes exhibit accelerated cell
cycle progression. The administration of diethylnitrosomaine, a
potent hepatocarcinogen, induced accelerated proliferation of
liver cells in the early phase, as well as lipid droplet accumula-
tion with increased proliferating cell numbers in the later phase,
in Pim-3 transgenic mice compared with wild-type mice.(38) Fur-
thermore, the incidence and burden of HCC was greater in Pim-
3 transgenic mice than in wild-type mice, and the transgenic
mice also had enhanced intratumoral vascular areas.(38) These
observations suggest that Pim-3 alone cannot cause HCC, but
can accelerate its development (probably by modulating cell
cycle progression), in the presence of a hepatocarcinogen.
Information is still sparse as to which molecules are phos-
phorylated by Pim-3 in addition to Bad. Pim-3 shows a high
sequence identity with Pim-1 even in their kinase domains
(Fig. 1). Moreover, both Pim-1 and Pim-3 bind to a consensus
peptide substrate (AKRRRRHPSGPPTA) with a markedly high
affinity, having Kd values in the range 40–60 nM, whereas the
affinity for Pim-2 is somewhat weaker (640 nM).(16) These
observations suggest that Pim-1 and Pim-3 may phosphorylate a
similar set of substrates and therefore the existing observations
regarding the biological functions of Pim-1 may provide clues
as to the function of Pim-3.
It has been shown that Pim-1 phosphorylates Cdc25A, thereby
increasing its phosphatase activity and the activity of cyclin D1-
associated kinases, which results in cell cycle progression.(39)
The Cdc25C-associated kinase 1 (C-TAK1) is a potent inhibitor
of Cdc25C, a protein that actively promotes cell cycle progres-
sion at the G2 ⁄M phase. By phosphorylating C-TAK1, Pim-1
inhibits its activity and eventually advances the cell cycle.(40)
Furthermore, Pim-1 can phosphorylate p21, another molecule
involved in cell cycle progression, at its threonine residues,
resulting in its relocation to the cytoplasm and enhanced protein
stability.(41,42) These effects are associated with increased cell
proliferation.(42) All Pim kinase members can bind to and phos-
phorylate the CDK inhibitor p27 at its threonine residues and
induce the binding of p27 to 14-3-3 protein, resulting in its
nuclear export and proteasome-dependent degradation.(43) More-
over, Pim-1 represses p27 gene transcription via the phosphory-
lation and inactivation of forkhead transcription factors FoxO1a
and FoxO3a.(43) The decreased p27 expression results in cell
cycle progression. Thus, it is tempting to speculate that Pim-3
can promote cell cycle progression and thus eventually contrib-
utes to carcinogenesis by modulating the function of molecules
that regulate cell cycle progression.
Mice deficient for all Pim kinases, designated as triple knock-
out (TKO) mice, are viable and fertile.(44) However, these TKO
mice display reduced body size at birth and throughout postnatal
life. The TKO mouse embryonic fibroblasts (MEF) exhibit
activated AMP-dependent protein kinase (AMPK), grow slowly1440in culture, and have decreased rates of protein synthesis, arising
from a decreased amount of 5¢-cap-dependent translation.(45)
Transduction of the Pim-3 gene alone into TKO MEF can
reverse AMPK activation, increase protein synthesis, and drive
growth to a similar level as in wild-type MEF.(45) Moreover,
Pim-3 expression can markedly increase the amount of c-Myc
and peroxisome proliferator-activated receptor c coactivator 1a
(PGC-1a), enzymes capable of regulating glycolysis and mito-
chondrial biogenesis.(45) Thus, Pim-3 may promote tumorigene-
sis by augmenting protein synthesis.
Originally, Pim-1 and Pim-2 were implicated in cell survival
to suppress myc-induced apoptosis.(5,7) Transgenic mice express-
ing El-Pim-1 and El-Myc succumb to lymphoma in utero
or around birth.(4) In contrast, El-Myc transgenic mice that
are deficient in the Pim-1 and Pim-2 genes exhibit delayed
lymphoma development.(46) Thus, Myc-driven tumorigenesis
depends on physiological levels of Pim-1 and Pim-2. Several
mechanisms have been proposed to explain the cooperation
between Myc and Pim kinases. For example, it has been sug-
gested that Myc recruits Pim-1 to the E-boxes of Myc target
genes, such as FOSL1 (Fra-1) and ID2, and that Pim-1 phos-
phorylates serine 10 of histone H3 on the nucleosome at the
Myc-binding sites, acting as a co-activator of Myc.(47) Consis-
tently, expression profile analysis has demonstrated that Pim-1
contributes to the regulation of approximately 20% of Myc-
regulated genes.(47) Moreover, Pim-1 and Pim-2 phosphorylate
c-Myc protein at its serine and threonine residues.(48) This
results in stabilization and subsequent enhancement of the tran-
scription activities of c-Myc protein. Furthermore, Pim-3 can
enhance c-Myc mRNA expression via activation of PGC-
1a.(45) Thus, Pim kinases can promote tumorigenesis by modu-
lating the activities of c-Myc.(5,7)
Thus, Pim-3 may contribute to tumorigenesis through four
main activities similar to those of the Pim family members,
namely Pim-1 and Pim-2: (i) the delivery of survival signaling
through phosphorylation of Bad; (ii) regulation of cell cycle pro-
gression; (iii) regulation of protein synthesis; and (iv) regulation
of Myc transcriptional activity (Fig. 4).
Biological Functions in Situations Other Than
Tumorigenesis
Both Pim-1 and Pim-3 have an important role maintaining the
self-renewal capacity of mouse embryonic stem cells in vitro.(29)
For example, Pim-3 is concentrated at the cellular lamelipodiadoi: 10.1111/j.1349-7006.2011.01966.x
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and is colocalized with focal adhesion kinase in endothelial
cells, with Pim-3 shRNA treatment impairing endothelial cell
spreading, migration, and proliferation, leading to a reduction in
tube-like structure in a Matrigel assay.(18) However, TKO mice
did not display any apparent abnormal phenotypes in embryo-
genesis and vascular development,(44) raising questions as to the
physiological relevance of these observations.
The expression of all Pim kinases is induced in the hippocam-
pus in response to stimuli that elicit long-term potentiation
(LTP).(2) Mice deficient for Pim-1 fail to consolidate enduring
LTP, but they preserve normal synaptic transmission and short-
term plasticity.(2) Ischemia or ischemia–reperfusion enhance the
expression of Pim-3 in the brain and heart.(19,20) Moreover, the
transfection of the Pim-3 gene into cardiomyocytes attenuates
ischemia–reperfusion injury through a p38 MAPK signaling
pathway.(20) Similarly, Pim-3 gene transduction increases Bcl-2
expression, dampens caspase-3 activation, and eventually pro-
tects against hepatic failure in D-galactosamine-sensitized rats
that are given lipopolysaccharide.(49)
Expression of Pim-3 has been detected in b-cells in the pan-
creatic islets.(50) Pim-3-deficient mice exhibit increased glucose
tolerance and increased insulin sensitivity. Moreover, Pim-3 can
negatively regulate insulin secretion by inhibiting the activation
of ERK1 ⁄2 through an interaction with suppressor of cytokine
signaling (SOCS) 6.(50) This contrasts with the effects of the
inhibition of another survival kinase, Akt, which can lead to
hyperglycemia.(9,10)
Pharmacologic Inhibition of Pim-3 Kinase
The crucial involvement of Pim kinases in several types of can-
cers indicates that Pim kinase inhibitors may be useful in the
treatment of malignant diseases.(51) Indeed, anti-Pim-1 antibody
or Pim-1 inhibitory peptide have been shown to inhibit tumor
growth in in vivo xenograft models using human cancer cell
lines.(52,53)
The crystal structure of Pim-1 and Pim-2 reveals the presence
of a unique hinge region that connects the two lobes of the pro-
tein kinase domain.(15–17) As a result, ATP binds to Pim kinases
in fundamentally different ways from how it binds to other pro-
tein kinases.(15,16) Thus, it may be feasible to develop a com-
pound that selectively inhibits Pim kinases and not other
serine ⁄ threonine kinases.(51) Several groups have reported small
molecule inhibitors against Pim kinases, including flavonol
quercetargetin,(54) imidazole[1,2-b]pyridazines,(55,56) bezylind-
ene-thiazolidine-2,4-dione,(57,58) and pyrrolo[2,3-a]carbazole.(59)
These molecules have been shown to inhibit cell proliferation of
human cancer cell lines in vitro and ⁄or in vivo. Similarly, weMukaida et al.have also found that stemonamide synthetic intermediates can
inhibit Pim-3, as well as Pim-1 and Pim-2, activity and reduce
tumor growth in in vivo xenograft models using a human pancre-
atic cancer cell line without causing any major adverse
effects.(60) Given an extraordinarily similar peptide substrate
identity between Pim-1 and Pim-3,(16) it may be difficult to
obtain an inhibitor specific to either Pim-1 or Pim-3 kinase.
Indeed, pyrrolo[2,3-a]carbazole potently inhibits Pim-1 and
Pim-3 kinase, but only weakly inhibits Pim-2, with IC50 values
of 0.57 ± 0.04, 0.04 ± 0.01, and >10 lM, respectively.(59) How-
ever, it remains to be investigated whether a specific inhibitor
against each of the members of the Pim family will provide any
advantage over multi-Pim kinase inhibitors.
Future Perspectives
It is known that Pim-3 kinase is constitutively active once it is
expressed. Pim-3 kinase is aberrantly expressed in malignant
lesions, but not normal tissues, of endoderm-derived organs
such as the liver, pancreas, colon, and stomach,(14,24–26) and
contributes to tumorigenesis by inhibiting the apoptosis of
tumor cells and promoting cell cycle progression. Although
Pim-3 is expressed robustly in vital organs such as the heart,
brain, and lungs,(14) the roles of Pim-3 under physiological
and pathological conditions remain unknown. However, a defi-
ciency of the Pim-3 gene does not result in apparent changes
in phenotype, suggesting that Pim-3 may be physiologically
dispensable. Unlike another survival kinase, namely Akt
kinase,(9) Pim kinases are not localized downstream of the
insulin receptor signaling pathway and therefore inhibition of
the Pim kinases has few effects on normal metabolism. Thus,
targeting Pim-3 may provide us with novel and safe molecular
targeting drugs for solid tumors, in which Pim-3 is aberrantly
expressed.
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